Abstract

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is the putative cause of coronavirus disease 2019 (COVID-19), a serious disease that has severely impacted the world. Although vaccines have been developed, it will take time to inoculate the global population. Current guidelines have focused on the treatment of severe cases in hospital settings; however, a void has been created regarding appropriate measures for those in the initial stage of COVID-19 and those experiencing moderate disease severity progressing to desaturation. We assessed clinical outcomes in patients with COVID-19 with pneumonia at initial presentation treated with corticosteroids.

Matéria original

Anterior

Thermal degradation of hazardous 3-layered COVID-19 face mask through pyrolysis: Kinetic, thermodynamic, prediction modelling using ANN and volatile product characterization

Próxima

TEMPOL inhibits SARS-CoV-2 replication and development of lung disease in the Syrian hamster model